Short answer
Sanara MedTech Inc. (SMTI) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per SMTI share, with stock component valued at $2.00.
Sanara MedTech Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per SMTI share, with stock component valued at $2.00
- Board-unanimous transaction creates a MiMedx subsidiary, subject to majority stockholder approval and regulatory clearances
- Specified stockholders controlling approximately 38.9% of voting power agreed to support the merger, materially strengthening approval certainty
- $9,660,336 company termination fee limits competing bids; MiMedx owes $22,540,785 if it fails to close when required
- Expected closing by July 29, 2027, extendable to January 29, 2028 for unresolved antitrust approvals; SMTI shares would then be delisted from Nasdaq
Item 7.01 · Regulation FD Disclosure
- Proposed MiMedx–Sanara business combination remains subject to regulatory approvals and Sanara stockholder approval
- Transaction timing and anticipated benefits remain uncertain, with potential abandonment if closing conditions fail
- Sanara may incur significant transaction costs, litigation exposure, operational disruption and a potential termination fee
- MiMedx plans Form S-4 registration statement containing Sanara proxy statement and MiMedx prospectus
- Investors should review the definitive proxy statement/prospectus before voting or making investment decisions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sanara MedTech Inc. 8-K filings
Get the next SMTI 8-K as it lands
Follow SMTI for push alerts, or ask the research agent what this filing means.